Komori
SanBio (4592) · RiskRestated

Repayment of CIRM Subsidy and Sales-Linked Royalty Obligation

First written in FY2018. 3 of 4 entries say "Restated". Latest entry: FY2023.

4entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2018 – FY20232018: 120182019: 120192020: 120202021: 020212022: 020222023: 12023
Same theme, other companies
Repayment of CIRM Subsidy and Sales-Linked Royalty ObligationA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2023RestatedAnnual report

    「C (if lump-sum repayment is not selected): Payment of a 2% royalty on sales for 10 years from the year of launch, or until payments reach a maximum of $180 million.」

    The terms of the CIRM grant were reaffirmed: lump-sum repayment upon commercialization or payment of 2% of post-launch sales for 10 years, up to a maximum of $180 million.
  2. FY2020RestatedAnnual report

    「If development is successful and the product is commercialized, the Company is required to repay the full amount of the grant in a lump sum or otherwise to the State of California. A royalty of 2% of sales is payable for 10 years from the year of launch, or until payments reach a maximum of $180 million.」

    The terms of the CIRM grant were reaffirmed: repayment upon commercialization or payment of 2% of post-launch sales for 10 years, up to a maximum of $180 million.
  3. FY2019RestatedAnnual report

    「If development is successful and the product is commercialized, the Company is required to repay the full amount of the grant in a lump sum or otherwise to the State of California. A royalty of 2% of sales is payable for 10 years from the year of launch, or until payments reach a maximum of $180 million.」

    The terms of the CIRM grant were reaffirmed: repayment upon commercialization or payment of 2% of post-launch sales for 10 years, up to a maximum of $180 million.
  4. FY2018First statedAnnual report

    「If development is successful and the product is commercialized, the Company is required to repay the full amount of the grant in a lump sum or otherwise to the State of California. A royalty of 2% of sales is payable for 10 years from the year of launch, or until payments reach a maximum of $180 million.」

    The terms of the CIRM grant were disclosed: repayment of the full amount upon commercialization, or payment of a 2% royalty on sales for 10 years after launch, up to a maximum of $180 million.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for SanBio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.